DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 19537/S-087
NDA 20780/S-044

SUPPLEMENT APPROVAL

Bayer HealthCare Pharmaceuticals, Inc.
Attention: Joseph Marini, MS, RPh
Associate Director, Regulatory Affairs – Established Products
100 Bayer Blvd. PO Box 0915
Whippany, NJ 07981-0915

Dear Mr. Marini:

Please refer to your Supplemental New Drug Applications (sNDA) dated and received February 03, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA #	Supplement	Dosage form	Strength
019537	S-087	CIPRO (ciprofloxacin hydrochloride) Tablets	250 mg, 500 mg, and 750 mg
020780	S-044	CIPRO (ciprofloxacin hydrochloride) Oral Suspension	5% (250 mg/5 mL), 10% (500 mg/5 mL)

These Prior Approval supplemental new drug applications provide for revisions to the U.S. Prescribing Information (PI) as follows:

Section 2, DOSAGE AND ADMINISTRATION

Subsections **2.1, Dosage in Adults** and **2.2, Dosage in Pediatric patients** were updated to recommend administration of oral suspension using the co-packaged graduated spoon.

Subsection **2.5, Directions for Reconstitution of the CIPRO Microcapsules for Oral Suspension** was updated to add the strengths in milligram and the corresponding volume in mL(s).

Subsection **2.6, Administration instructions for CIPRO for Oral suspension After Reconstitution** was updated to include a graphic diagram of the co-packaged graduated teaspoon and provide proper cleaning information and additional administration instruction.

Subsection **2.7, Dosing of CIPRO for Oral Suspension using the Co-Packaged Spoon in Adults and Pediatric-Patients** was added to include tables to determine the recommended dose in the pediatric population using the packaged graduated spoon.

Section 5, WARNINGS AND PRECAUTIONS, Subsection **5.15, Potential Risks with concomitant Use of Drug Metabolized by Cytochrome P450 1A2 Enzymes** was updated to add zolpidem

Section 7, DRUG INTERACTIONS, was updated to add zolpidem to the list of drugs that are affected by and affecting Cipro.

Section 8, USE IN SPECIFIC POPULATIONS, subsection **8.4, Pediatric use,** was updated to add clarity to the term arthropathy.

Sections 15, REFERENCES, were updated.

Section 17, PATIENT COUNSELING INFORMATION, was added to provide the patient with proper cleaning information.

In addition minor editorial changes were made thorough out the PI.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert,Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).
All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft guidance for industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm. D., Regulatory Health Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Acting Deputy Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

DMITRI IARIKOV
07/26/2017